• Cy5 amine (non-sulfonated): Labeling Guide

  2026-09-25

  Cy5 amine (non-sulfonated) provides a primary amine for attaching a Cy5 fluorophore to suitable activated biomolecules in fluorescence workflows. It is water-insoluble, so it should be dissolved in an organic co-solvent before coupling and is not suitable for direct use in aqueous labeling reactions.

• AG-221 (Enasidenib) in IDH2-Mutant AML Research

  2026-09-25

  AG-221 (Enasidenib) is a selective mutant IDH2 inhibitor used to investigate 2-hydroxyglutarate reduction and differentiation in IDH2-mutant AML models. Research on CD44-mediated metabolic rewiring adds a complementary mechanism to study alongside IDH inhibition, but does not establish that AG-221 directly targets CD44.

• Biotin-tyramide for Spatial Signal Amplification

  2026-09-24

  Biotin-tyramide turns localized HRP activity into a sensitive, spatially anchored signal for immunohistochemistry and in situ hybridization. This practical guide covers a careful TSA workflow, pilot conditions, controls, and how to distinguish fixed-sample signal amplification from live-cell RNA proximity labeling.

• From MMP Signaling to BBB Integrity: Doxycycline Hyclate

  2026-09-24

  A translational framework for using Doxycycline hyclate to probe MMP-associated blood–brain barrier injury. We examine a mouse arsenic study, outline experimental design priorities, and distinguish mechanistic evidence from broader antiviral, antimalarial, and vascular research claims.

• How Fasting Rewires Translation to Drive Ketogenesis

  2026-09-23

  Yang and colleagues show that fasting can reduce global protein synthesis while selectively increasing translation of liver mRNAs needed for lipid catabolism and ketone production. Their work identifies a fatty-acid–AMPK–MNK–P-eIF4E pathway and finds that inhibiting P-eIF4E during a ketogenic diet can restrain pancreatic tumor growth in the tested model.

• AG-120 (Ivosidenib) Workflows for IDH1 Research

  2026-09-23

  Build a mechanism-first workflow with AG-120 (Ivosidenib) that links mutant IDH1 inhibition to 2-hydroxyglutarate reduction, metabolic rewiring, and differentiation phenotypes. The approach combines metabolite, viability, and myeloid readouts to improve interpretation in AML models and ex vivo samples.

• From CTD Phosphorylation to Cysteine Accessibility

  2026-09-22

  A translational framework connecting RNA polymerase II CTD phosphorylation, chemical-proteomic validation, and MTSEA-biotin as a practical tool for testing protein accessibility and regulatory mechanism.

• ARCA EGFP mRNA for Transfection Workflows

  2026-09-22

  ARCA EGFP mRNA provides a fast, direct fluorescence readout for separating delivery performance from downstream protein expression in mammalian cells. Its ARCA cap and approximately 100-nucleotide poly(A) tail make it a practical control for lipid nanoparticle benchmarking, transfection optimization, and early-stage assay development.

• Diphenyleneiodonium chloride Workflow Guide

  2026-09-21

  Diphenyleneiodonium chloride enables side-by-side interrogation of oxidase-linked ROS and GPR3-associated cAMP responses, but its broad target profile demands careful controls. This workflow translates a recent citrus canker study into practical redox, ferroptosis-oriented, and cell-signaling assay strategies.

• Repaglinide and the Energy–DNA Repair Axis

  2026-09-21

  Energy deficiency can reshape DNA repair through ATG4B nuclear translocation and disruption of PRMT1-dependent MRE11 regulation in acute myeloid leukemia. This article positions Repaglinide as a carefully bounded metabolic-context perturbation for translational studies—not as a validated ATG4B inhibitor or leukemia treatment—and outlines how to build a rigorous workflow around that distinction.

• Isoproterenol Sulfate Dihydrate in SAN Research

  2026-09-20

  Isoproterenol sulfate dihydrate provides a controllable acute stimulus for beta-adrenergic receptor signaling in human SAN-plexus assembloids. Used alongside electrophysiology, calcium imaging, and neural co-culture comparisons, it helps distinguish intrinsic pacemaker maturation from reversible sympathetic-like modulation.

• AG-120 and the Metabolic Logic of IDH1 AML

  2026-09-19

  AG-120 (Ivosidenib) translates mutant IDH1 biology into a measurable differentiation strategy for AML research. By connecting 2-hydroxyglutarate reduction with CD44-mediated metabolic rewiring, this article outlines how translational teams can design stronger pharmacodynamic, resistance, and combination studies.

• From Interaction Maps to Translational Decisions

  2026-09-18

  Protein interaction data become valuable when they change a biological or development decision. This thought-leadership article connects the genomic and field findings from a recent Trichoderma–peanut study with practical strategies for validating candidate protein partners. It explains how Fc capture, magnetic separation, controls, elution choices, and orthogonal confirmation can turn a co-IP experiment into a defensible evidence chain. The Protein A/G Magnetic Co-IP/IP Kit is presented not as a substitute for experimental design, but as a standardized capture layer for moving from candidate discovery to mechanistic confidence.

• (R)-MG132 for Causal Proteasome Assays

  2026-09-18

  (R)-MG132 is an inactive MG-132 enantiomer for separating proteasome-dependent effects from solvent, cytotoxic, and off-target responses. This article presents a causal assay framework linking stereochemical controls to HNRNPU lactylation and serine-metabolism studies.

• Tamoxifen Workflows for Cancer and CreER Research

  2026-09-17

  Tamoxifen supports both established estrogen-receptor studies and newer immune-oncology workflows that pair macrophage reprogramming with radiotherapy. This guide translates those use cases into practical preparation, assay-design, CreER controls, and troubleshooting strategies.

8602 records 1/574 page Next 12345 下5页 Last page